

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Friday, August 19, 2005

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,DWPI; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L9	L1 and L2 and ulcer	30
<input type="checkbox"/>	L8	L6 and "anti-inflammatory drug"	4
<input type="checkbox"/>	L7	L6 and antibiotics	17
<input type="checkbox"/>	L6	L1 and L2 and L5	20
<input type="checkbox"/>	L5	dermatitis	26080
<input type="checkbox"/>	L4	burn	226622
<input type="checkbox"/>	L2	"wound healing"	25273
<input type="checkbox"/>	L1	p43	116945

END OF SEARCH HISTORY

WEST Search History

DATE: Friday, August 19, 2005

Hide? **Set Name** **Query** **Hit Count**

DB=USPT; PLUR=YES; OP=OR

<input type="checkbox"/>	L7	L6 and dermatitis	36
<input type="checkbox"/>	L6	L5 and cream	128
<input type="checkbox"/>	L5	L4 and L3	212
<input type="checkbox"/>	L4	L2 and ointment	765
<input type="checkbox"/>	L3	"wound healing"	9620
<input type="checkbox"/>	L2	IL-8 or Interleukin-8	3238

END OF SEARCH HISTORY

First Hit

End of Result Set

L6: Entry 20 of 20

File: DWPI

Jun 2, 2005

DERWENT-ACC-NO: 2004-145613
DERWENT-WEEK: 200537
COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Use of p43 polypeptide, for the manufacture of pharmaceutical composition intended to stimulate wound healing in a subject

INVENTOR: KIM, S; KIM, S H

PATENT-ASSIGNEE: UNIV SEOUL NAT IND FOUND (UYSEN)

PRIORITY-DATA: 2002KR-0042858 (July 22, 2002)

Search Selected	Search ALL	Clear
-----------------	------------	-------

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<input type="checkbox"/> <u>US 20050119175 A1</u>	June 2, 2005		000	A61K038/18
<input type="checkbox"/> <u>EP 1384486 A1</u>	January 28, 2004	E	020	A61K038/19
<input type="checkbox"/> <u>KR 2004009048 A</u>	January 31, 2004		000	A61K038/16

DESIGNATED-STATES: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC MK
NL PT RO SE SI SK TR

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
US20050119175A1	July 22, 2003	2003US-0623567	
EP 1384486A1	July 22, 2003	2003EP-0016724	
KR2004009048A	July 22, 2002	2002KR-0042858	

INT-CL (IPC): A61 K 38/16; A61 K 38/18; A61 K 38/19; A61 P 17/02

ABSTRACTED-PUB-NO: EP 1384486A

BASIC-ABSTRACT:

NOVELTY - Using one or more polypeptides (I) chosen from a polypeptide having a fully defined p43 sequence of 312 amino acids as given in the specification and a polypeptide having 70% or more sequence homology with (SI), for the manufacture of the pharmaceutical composition (II) which is intended to stimulate wound healing in a subject, is new.

ACTIVITY - Vulnerary; Antiulcer; Dermatological; Antiallergic; Antiinflammatory.

MECHANISM OF ACTION - Induction of macrophage/monocyte and endothelial cell; Re-epithelialization; Proliferation of fibroblasts; Angiogenesis.

Induction of macrophage/monocyte and endothelial cell was studied as follows. 5 day-aged wounds were isolated with 3 mm of adjacent normal tissue. The isolated wounds were fixed in 4% paraformaldehyde in phosphate buffered saline (PBS) and then frozen in the OCT compound.

<http://westbrs:9000/bin/gate.exe?f=DOC1&queue=yes&STATE=mas9u1.25.20&USERID=blee3&...> 8/19/2005

The cyro-sections of the wounds were analyzed by immune-fluorescence. To detect macrophage/monocyte and endothelial cells, the frozen sections were incubated in 1.7 micro g/ml of anti-mouse MOMA-2 antibody and 1.0 micro g/ml of anti-CD31 antibody that are specific to the cells, respectively. After incubation for 1 hour with the primary antibodies, 1.0 micro g/ml of flourescein isothiocyanate (FITC) conjugated secondary antibody was added and further incubated for 1 hour. The wounds were then counter stained with propidium iodide (1 micro g/ml), mounted on slides and investigated using confocal immunofluorescence microscopy. The wound tissues of the wild type mice treated with p43 (WT +p43) showed the enrichment of the macrophage/monocyte while the wound tissues of the homozygous mutant mice (Ho) showed fewer numbers of the macrophage/monocyte. Also, the immunostaining of the wounds with the antibody specific to enothelial cells showed that vascularization was also significantly enhanced in the p43-treated wounds while the reverse was the case in the p43 mutants.

USE - (I) is useful for the manufacture of the pharmaceutical composition (II) which is intended to stimulate wound healing in a subject. The wound is chosen from burn, ulcer, trauma, post-surgical, post-child birth, chronic wound and dermatitis. The burn is chosen from sun burn, chemical burn, radiation burn, and thermal burn. The ulcer is chosen from pressure ulcer, plaster ulcer and decubitus ulcer. The chronic wound is chosen from bedsores, pressure sores, diabetes-related and poor circulation-related. The dermatitis is chosen from impetigo, intertrigo, folliculitis and eczema (claimed).

DESCRIPTION OF DRAWING(S) - The figure shows a schematic drawing showing where the gene trap is inserted within p43 mutant allele.

ABSTRACTED-PUB-NO: EP 1384486A
EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.1/1

DERWENT-CLASS: B04 D21
CPI-CODES: B04-C01G; B04-N04A; B12-M01A; B12-M02B; B12-M02E; B14-L01; B14-N17; D08-B09A1;